Morepen Laboratories Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/by214m8npf3f7aq1bfxw9sx5.pdf

Key Takeaways


Medical Devices: The Annuity Moat

Sushil Suri: "It's like a typical printer cartridge model. And this is a locked-in system. Our meter can use only our strips, and our strips work only on our meters. So that way, it's like a regular annuity business."

Margin & Profitability Reset


API Business & Export Shift


Capacity Expansion & Capex


New Initiatives & Distribution

Sushil Suri: "Most of the companies are focusing on the doctors' chamber and of course the products are very costly, semaglutide, liraglutide. So many products are being talked and there are injectables also. But we have seen the trend, the consumer still wants something at home in the comfort of home, which he can follow at peace."

The Morepen 2.0 Thesis

Sushil Suri: "This is Morepen 2.0. Like whatever we have done in the past, so we, of course, as a debt-free company, cleared all the debts. And now we are in a growth phase with the new capital in hand."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15-20% top-line growthOngoing (consistent with historical 18% CAGR)
EBITDA margin expansion3-4% improvement from current ~12% toward 15%Over the next 2-3 years
PAT marginReach double-digit PAT marginsOver the next three years
Capacity operationalNew API (400 KL to 600 KL), glucometer, and BP monitor capacities fully operationalWithin 12-18 months
BP monitor revenueCross ₹100 cr (vs ₹80 cr last year)This fiscal year
Chip backward integrationCommercialization of in-house chip manufacturingDuring this financial year
Retail outlet expansionGrow from 128,000 to 3 lakh retail outletsOver the next three years
API product mix shiftNew products (Sitagliptin, Linagliptin, Dapagliflozin, Empagliflozin) reach 30-35% of API revenueBy 2030
Medical devices export dominanceExports become dominant in medical devices businessIn another 2-3 years, after certifications

Key Metrics

MetricQ1 FY25
Gross revenue₹458.64 cr, +14% YoY
Pharma revenue₹320 cr, +11% YoY
Medical devices revenue₹138 cr, +20% YoY
Medical devices share of revenue30.2%, up from 26% last fiscal
EBITDA₹55.05 cr, +93% YoY, highest ever in 40 years
EBITDA margin12%, up from 7.07% in Q1 last year
Profit before tax+135% YoY
Profit after tax₹36 cr, +147% YoY, vs ₹14.63 cr last year
PAT margin7.89%, up from 3.63% in Q1 last year
EPS (TTM)₹2.30, up from ₹1.88 as on financial closing
EPS (Q1 FY25)₹0.71 per share
Export business growth+31% YoY
Cash generation₹53 cr, +91% YoY
Medical devices installed meter base1.23 cr meters
Glucose strips sold12 cr strips in Q1, vs 36 cr strips in all of last year
BP monitors revenue₹26 cr in Q1, vs ₹80 cr in all of last year
BP monitors growth29% YoY
Glucometers growth17% YoY
API market share: Loratadine67%
API market share: Montelukast44%
API market share: Desloratadine26%
API market share: Fexofenadine22%
API export share71% of API business
Europe API growth+130% YoY
South America API growth+80% YoY
U.S. API growth-33% YoY, due to high base
India API growth-16% YoY, purposeful reduction
QIP amount raised₹200 cr, 3.68 cr new shares issued
Institutional holding10.61%–10.67%, up from 3%–4% earlier
Capex from QIP proceeds₹123 cr allocated
API capacity expansion400 KL to 600 KL
Glucometer capacity expansion0.25 cr to 0.5 cr units
Glucose strips capacity expansion50 cr to 70 cr units
BP monitor capacity expansion0.12 cr to 0.25 cr units
Tax rate~26%
Asset turnover: API7.2
Asset turnover: Medical devices~10.5, expected to stabilize at 8.5–9 after backward integration
Working capital days: Medical devices~70 days last fiscal
Working capital days: API90+ days
Retail outlets128,000 currently, targeting 3 lakh in three years
Revenue growth expectation15%–20% (Sushil Suri), 15%–18% (Ajay Sharma)